Worksite Cancer Screening Boosts Employee Morale

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designed to help reduce cancer morbidity and mortality among employees, but have the added benefit of enhancing the employer's corporate image and boosting employee morale.

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designedto help reduce cancer morbidity and mortality among employees,but have the added benefit of enhancing the employer's corporateimage and boosting employee morale.

"Cancer screening and education programs enhance a company'sreputation as a leader in employee health initiatives," saidRobert C. Black, president of Zeneca Pharmaceuticals, at the secondannual conference of the Industries' Coalition Against Cancer(ICAC).

Mr. Black noted that the worksite screening program at Zenecahas been applauded both within the company and within the communitywhere it operates, and receives frequent media attention, especiallythe breast cancer program, which has found eight cases of breastcancer in just 5 years.

Zeneca is viewed as a leader in helping large and small companiesand organizations develop and implement breast cancer screeningprograms, he said, due to its sponsorship of two Public BroadcastingSystem video conferences on worksite screening, as well as ICAC.

He said that the screening programs have helped improve employeemorale company wide. "Those who participate in our cancerscreening program have become its most effective promoters,"he said. "They truly become ambassadors for the company,both within its walls and within the local community."

Furthermore, when cancers are found, he said, Zeneca employeesrally around their coworkers with cancer by working extra hoursto give them time off, giving up vacation time to take over assignments,and providing a support system with hospital and home visits.In short, he said, "our employees do all the things thatmembers of a family, in this case a corporate family, do for eachother."

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content